Viking Therapeutics (VKTX) stock is soaring 5.05% in pre-market trading on Wednesday, following the release of mid-stage trial results for its experimental weight-loss pill, VK2735. Despite falling short of the highest Wall Street expectations, the drug's performance and analyst reactions appear to be driving positive investor sentiment.

The mid-stage trial showed that VK2735 helped patients lose 12.2% of their body weight, which fell short of Wall Street's top-end expectations of 15%. However, many analysts remain optimistic about the drug's potential. Oppenheimer maintained an "Outperform" rating, stating that the drug's profile remains favorable with room for improvement through dose adjustments. BTIG, with a "Buy" rating, asserted that the drug's "competitive positioning remains intact despite market selloff" after the mid-stage data.

While some concerns were raised about the safety and tolerability profile at higher doses, analysts from J.P.Morgan suggest that starting at lower doses and gradually increasing could lead to a competitive tolerability profile without significantly impacting efficacy in longer studies. The market's positive reaction, despite the mixed results, indicates that investors are focusing on the drug's potential in the competitive obesity treatment landscape.